Redefining Cancer Care with CAR-T Cell Therapy

Chimeric Antigen Receptor (CAR) T-cell therapy has emerged as a transformative force in 21st-century cancer immunotherapy, offering new hope in the treatment of hematologic malignancies once considered untreatable. At the forefront of this advancement is the Bone Marrow Transplant (BMT) and Cellular Therapy Unit at Yashoda Hospitals, where cutting-edge science meets clinical excellence.

With world-class infrastructure, advanced laboratory capabilities, and a highly experienced multidisciplinary team, Yashoda Hospitals delivers precision-driven, patient-centered cellular therapies with the highest standards of safety and care.

CAR T-Cell Therapy: A Next-Generation Approach

CAR T-cell therapy is a sophisticated form of personalized immunotherapy that involves engineering a patient’s own T cells to recognize and attack cancer cells. This targeted approach has demonstrated long-lasting responses in carefully selected patients and represents a major evolution in cancer treatment strategy.

Indications for CAR-T Cell Therapy

CAR T-cell therapy is currently approved for specific indications, including:

• Diffuse Large B-Cell Lymphoma (DLBCL)
• Mantle Cell Lymphoma (MCL)
• Follicular Lymphoma (FL)
• B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
• Multiple Myeloma (MM)

Building Excellence in Personalized Immunotherapy

As one of India’s leading quaternary care centers, Yashoda Hospitals continues to set new benchmarks in cellular and immunotherapy-based cancer care. Our BMT and Cellular Therapy Unit plays a central role in bringing these next-generation therapies to patients, backed by innovation, research, and a deep commitment to quality. With an integrated ecosystem that combines clinical expertise, state-of-the-art infrastructure, and a dedicated team of specialists, Yashoda Hospitals stands as a trusted destination for advanced oncology delivering care that is not only technologically sophisticated, but also deeply compassionate.